Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report

Raja Majid Afzal; Jeppe Romme Christensen; Rosa Maja Møhring Gynthersen; Anne-Mette Lebech; Morten Blinkenberg; Helene Mens

doi:10.1177/13524585241235542

Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report

Raja Majid Afzal^*, Jeppe Romme Christensen, Rosa Maja Møhring Gynthersen, Anne-Mette Lebech, Morten Blinkenberg, Helene Mens

^*Corresponding author af dette arbejde

3 Citationer (Scopus)

Abstract

OBJECTIVE: To describe a case of neoehrlichiosis, an emerging opportunistic tick-borne infection, in a patient with multiple sclerosis (MS) treated with ocrelizumab.

METHODS: This is a case study.

RESULTS: Our patient developed clinical infection over several months while on ocrelizumab and was ultimately diagnosed with neoehrlichiosis, caused by the bacteria Neoehrlichia mikurensis. Resolution of symptoms began within a few days after the initiation of antibiotic treatment.

CONCLUSION: We describe the first probable case of ocrelizumab-associated neoehrlichiosis in a patient with MS. Clinicians should be aware of this potentially debilitating and life-threatening infection in patients receiving CD20-depleting therapy.

Originalsprog	Engelsk
Tidsskrift	Multiple Sclerosis Journal
Vol/bind	30
Udgave nummer	8
Sider (fra-til)	1081-1083
Antal sider	3
ISSN	1352-4585
DOI	https://doi.org/10.1177/13524585241235542
Status	Udgivet - jul. 2024

Adgang til dokumentet

10.1177/13524585241235542

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{0c2d19e22f704ebbb5b21dabd0b384d3,

title = "Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report",

abstract = "OBJECTIVE: To describe a case of neoehrlichiosis, an emerging opportunistic tick-borne infection, in a patient with multiple sclerosis (MS) treated with ocrelizumab.METHODS: This is a case study.RESULTS: Our patient developed clinical infection over several months while on ocrelizumab and was ultimately diagnosed with neoehrlichiosis, caused by the bacteria Neoehrlichia mikurensis. Resolution of symptoms began within a few days after the initiation of antibiotic treatment.CONCLUSION: We describe the first probable case of ocrelizumab-associated neoehrlichiosis in a patient with MS. Clinicians should be aware of this potentially debilitating and life-threatening infection in patients receiving CD20-depleting therapy.",

keywords = "Adult, Antibodies, Monoclonal, Humanized/adverse effects, Female, Humans, Immunologic Factors/adverse effects, Middle Aged, Multiple Sclerosis/drug therapy, neoerhlichiosis, Multiple sclerosis, infection, ocrelizumab, immunodeficiency, B-cell depleting therapy",

author = "Afzal, {Raja Majid} and {Romme Christensen}, Jeppe and Gynthersen, {Rosa Maja M{\o}hring} and Anne-Mette Lebech and Morten Blinkenberg and Helene Mens",

year = "2024",

month = jul,

doi = "10.1177/13524585241235542",

language = "English",

volume = "30",

pages = "1081--1083",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "8",

}

TY - JOUR

T1 - Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis

T2 - A case report

AU - Afzal, Raja Majid

AU - Romme Christensen, Jeppe

AU - Gynthersen, Rosa Maja Møhring

AU - Lebech, Anne-Mette

AU - Blinkenberg, Morten

AU - Mens, Helene

PY - 2024/7

Y1 - 2024/7

N2 - OBJECTIVE: To describe a case of neoehrlichiosis, an emerging opportunistic tick-borne infection, in a patient with multiple sclerosis (MS) treated with ocrelizumab.METHODS: This is a case study.RESULTS: Our patient developed clinical infection over several months while on ocrelizumab and was ultimately diagnosed with neoehrlichiosis, caused by the bacteria Neoehrlichia mikurensis. Resolution of symptoms began within a few days after the initiation of antibiotic treatment.CONCLUSION: We describe the first probable case of ocrelizumab-associated neoehrlichiosis in a patient with MS. Clinicians should be aware of this potentially debilitating and life-threatening infection in patients receiving CD20-depleting therapy.

AB - OBJECTIVE: To describe a case of neoehrlichiosis, an emerging opportunistic tick-borne infection, in a patient with multiple sclerosis (MS) treated with ocrelizumab.METHODS: This is a case study.RESULTS: Our patient developed clinical infection over several months while on ocrelizumab and was ultimately diagnosed with neoehrlichiosis, caused by the bacteria Neoehrlichia mikurensis. Resolution of symptoms began within a few days after the initiation of antibiotic treatment.CONCLUSION: We describe the first probable case of ocrelizumab-associated neoehrlichiosis in a patient with MS. Clinicians should be aware of this potentially debilitating and life-threatening infection in patients receiving CD20-depleting therapy.

KW - Adult

KW - Antibodies, Monoclonal, Humanized/adverse effects

KW - Female

KW - Humans

KW - Immunologic Factors/adverse effects

KW - Middle Aged

KW - Multiple Sclerosis/drug therapy

KW - neoerhlichiosis

KW - Multiple sclerosis

KW - infection

KW - ocrelizumab

KW - immunodeficiency

KW - B-cell depleting therapy

UR - http://www.scopus.com/inward/record.url?scp=85186555517&partnerID=8YFLogxK

U2 - 10.1177/13524585241235542

DO - 10.1177/13524585241235542

M3 - Journal article

C2 - 38424745

SN - 1352-4585

VL - 30

SP - 1081

EP - 1083

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 8

ER -

Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater